TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
ANDOVER, Mass., April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at .
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
332-895-3222
[email protected]
SOURCE TransMedics Group, Inc.
ANDOVER, Mass., April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
馬薩諸塞州安多弗,2024年4月16日 /PRNewswire/ — 正在改變終末期肺部、心臟和肝衰竭患者器官移植療法的醫療技術公司TransMedics Group, Inc.(“TransMedics”)(納斯達克股票代碼:TMDX)今天宣佈,將在2024年4月30日星期二收盤後發佈2024年第一季度的財務業績。TransMedics管理團隊將從美國東部時間下午 4:30 /太平洋時間下午 1:30 開始舉行相應的電話會議。
Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at .
有興趣收聽電話會議的投資者可以撥打(866)807-9684(國內來電者撥打(412)317-5415,國際來電者可以撥打(412)317-5415,並要求加入TransMedics電話會議。該活動的直播和存檔網絡直播將在TransMedics網站的 “投資者” 部分播出,網址爲 。
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
關於 TransMedics Group, Inc.
TransMedics是便攜式體外熱灌注和移植供體器官評估領域的全球領導者。該公司總部位於馬薩諸塞州安多弗,成立的目的是解決對更多更好的移植器官的未得到滿足的需求,並開發了保護器官質量、在移植前評估器官活力的技術,並有可能提高捐贈器官在治療終末期心臟、肺和肝衰竭方面的利用率。
Investor Contact:
Brian Johnston
332-895-3222
[email protected]
投資者聯繫人:
布萊恩·約翰斯頓
332-895-3222
[電子郵件保護]
SOURCE TransMedics Group, Inc.
來源 TransMedics Group, Inc.
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧